Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.75 |
| ▸ | PI4KA | P42356 | 3/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | ADCY5 | O95622 | 9/20 | 0.64 |
| ▸ | AHCY | P23526 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12321001 | 1.00 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30315880 | 1.00 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5188585 | 1.00 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL987094 | 1.00 | ADORA2A (0.75) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9470633 | 0.90 | ADORA2A (0.71) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28984637 | 0.86 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL27459374 | 0.84 | ADORA2A (0.77) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9685991 | 0.83 | ADORA2A (0.50) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10474172 | 0.82 | ADCY5 (0.74) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9309056 | 0.82 | ADORA2A (0.69) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| US-20070270441-A1 | Combination | ALTANA PHARMA AG (DE) | 2007-11-22 | — | — | US | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| EP-1448202-A1 | COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA Pharma AG (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | disclosed |
| CN-1031132-C | Carbocyclic adenosine analogs useful as immunosuppressants | MARION MERRELL DOW INC (US) | 1996-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | ADORA2A 4072/4885PI4KA 3876/4885PI4K2B 4151/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | ADORA2A 1424/4885PI4KA 3875/4885PI4K2B 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.